$OMER News

Omeros: YARTEMLEA Is Off To A Blistering Start

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Q2 Adj. EPS $0.02 Beats $(0.27) Estimate, Sales $28.529M Beat $12.700M Estimate

Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights

Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return

Omeros: Yartemlea Faces Headwinds While We Wait On Pipeline Developments

Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?

Why Is OMER Stock Falling Today?

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

HC Wainwright & Co. Maintains Buy on Omeros, Lowers Price Target to $33

FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide

Omeros Gets EMA CHMP Negative Opinion On Narsoplimab In TA‑TMA; Co. To Request Re‑Examination And Seek Ad Hoc Expert Group Review

Omeros Announces Webcast Details for Annual Meeting of Shareholders

HC Wainwright & Co. Reiterates Buy on Omeros, Maintains $40 Price Target

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros (OMER) Q1 2026 Earnings Transcript

Omeros Corporation Q1 2026 Earnings Call Summary